MedTrace Logo

A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants

NCT05053165 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2022-09-06

No results posted yet for this study

Summary

The study is designed to assess the safety and tolerability of multiple ascending doses of LB-P6 or LB-P8 in healthy participants.

Conditions

Interventions

DRUG

LB-P6

Healthy subjects will be randomized to receive LB-P6 once daily orally

DRUG

LB-P8

Healthy subjects will be randomized to receive LB-P8 once daily orally

DRUG

Placebo

Healthy subjects will be randomized to receive placebo once daily orally

Sponsors & Collaborators

  • LISCure Biosciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-04
Primary Completion
2022-04-01
Completion
2022-06-29

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05053165 on ClinicalTrials.gov